Materials and Methods
- Merat S.
- Casanada F.
- Sutphin M.
- Palinski W.
- Reaven P.D.
Renal Lipid and Proteoglycan Accumulation
|0% Diet||0.12% Diet|
|Body weight (g), study end||23.3 ± 1.9||21.8 ± 1.0||28.0 ± 2.9||23.7 ± 0.7|
|Glycated hemoglobin (%)||7.5 ± 0.4||8.9 ± 1.1||7.0 ± 0.2||11.8 ± 1.0|
|Plasma cholesterol (mg/dL)||374 ± 19||410 ± 53||903 ± 154||774 ± 51|
|Triglycerides (mg/dL)||118 ± 54||143 ± 42||103 ± 25||251 ± 58|
|Plasma TGF-β (pg/mL)||78 ± 78||2936 ± 803||1101 ± 361||2377 ± 725|
|Renal weight/ body weight (mg/g)||5.0 ± 0.5||6.0 ± 0.7||4.6 ± 0.2||6.2 ± 0.3|
|Glomerular cross sectional area (μm2)||3954 ± 281||3717 ± 233||3777 ± 170||4946 ± 324|
|Systolic blood pressure (mmHg)||120 ± 6||120 ± 10||112 ± 8||114 ± 12|
Development of Diabetic Nephropathy
Diabetes Increases Glomerular Lipid Accumulation
Diabetes Increases Glomerular Biglycan Accumulation
Renal ApoB Colocalizes with Biglycan
- Ziyadeh F.N.
- Hoffman B.B.
- Han D.C.
- Iglesias-De La Cruz M.C.
- Hong S.W.
- Isono M.
- Chen S.
- McGowan T.A.
- Sharma K.
- Fellstrom B.C.
- Jardine A.G.
- Schmieder R.E.
- Holdaas H.
- Bannister K.
- Beutler J.
- Chae D.W.
- Chevaile A.
- Cobbe S.M.
- Gronhagen-Riska C.
- De Lima J.J.
- Lins R.
- Mayer G.
- McMahon A.W.
- Parving H.H.
- Remuzzi G.
- Samuelsson O.
- Sonkodi S.
- Sci D.
- Suleymanlar G.
- Tsakiris D.
- Tesar V.
- Todorov V.
- Wiecek A.
- Wuthrich R.P.
- Gottlow M.
- Johnsson E.
- Zannad F.
- Supplemental Figure S1
A: Non-fasting tail vein blood glucose was measured with a Freestyle Flash glucometer at the indicated times. B: Mouse weight was measured at the indicated times. Solid symbols represent non-diabetic mice, open symbols represent diabetic mice. Squares represent mice on the 0% cholesterol diet, circles represent mice on the 0.12% cholesterol diet. Data shown is mean ± SEM from 7 to 14 per group.
- Supplemental Figure S2
A: Renal versican content. B: Renal TGF-β content. Total renal protein was analyzed by Western blot analysis for renal versican or TGF-β content. Each lane shows versican or TGF-β, as indicated, from one mouse per group, representative of 4 mice per group. NonDM indicates non-diabetic group, DM indicates diabetic group. Actin was used as the loading control. C: Renal biglycan and TGF-β content determined by densitometry of Western blot analyses was analyzed by linear regression. Solid symbols represent non-diabetic mice, open symbols represent diabetic mice. Squares represent mice on the 0% cholesterol diet, circles represent mice on the 0.12% cholesterol diet. Figure depicts four per group for all groups. r = 0.873, P < 0.001, dashed lines represent 95% confidence intervals.
- Supplemental Figure S3
Shown is a representative section from a diabetic LDLR−/− mouse fed the 0.12% cholesterol diet immunostained for decorin (red), apoB (green), nuclear DAPI stain (blue), and the merged image (colocalization yellow).
- Immunohistological localization of lipoproteins in the glomeruli in renal disease: specifically apoB and apoE.Clin Nephrol. 1991; 36: 127-133
- lipoproteins and lipoprotein receptors in glomeruli in human kidney diseases.Kidney Int. 1993; 43: 918-927
- Interactions between lipoproteins, glomerular cells and matrix.Miner Electrolyte Metab. 1993; 19: 149-164
- Intraglomerular lipid deposition in routine biopsies.Clin Nephrol. 1991; 36: 67-75
- The glomerular mesangium.Kidney Int. 1980; 17: 141-154
- Interactions of low density lipoprotein with rat mesangial cells.Kidney Int. 1989; 35: 1168-1174
- Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro.Kidney Int. 1991; 39: 858-866
- Foam cells generated by a combination of hyperglycemia and hyperlipemia in rats.Pathol Int. 2004; 54: 904-913
- Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice.Am J Nephrol. 2004; 24: 20-31
- Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice.J Lipid Res. 2010; 51: 1464-1470
- Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease.Histol Histopathol. 2002; 17: 497-505
- Cellular lipid metabolism and the role of lipids in progressive renal disease.Am J Nephrol. 2004; 24: 46-53
- Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus.Histol Histopathol. 1998; 13: 169-179
- The response-to-retention hypothesis of early atherogenesis.Arterioscler Thromb Vasc Biol. 1995; 15: 551-561
- Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.Circulation. 2007; 116: 1832-1844
- Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis.Rev Endocr Metab Disord. 2008; 9: 289-300
- Proteoglycans and glycosaminoglycans synthesized in vitro by mesangial cells from normal and diabetic rats.Biochim Biophys Acta. 1996; 1290: 18-28
- The effect of glucose on proteoglycans produced by cultured mesangial cells.Diabetes. 1993; 42: 1815-1822
- The extracellular matrix in diabetic nephropathy.Am J Kidney Dis. 1993; 22: 736-744
- Proteoglycans can mediate renal lipoprotein retention.Diabetologia. 2006; 49: 1115-1116
- Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin.FASEB J. 2001; 15: 559-561
- Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease.Kidney Int. 2000; 57: 487-498
- Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet.Arterioscler Thromb Vasc Biol. 1999; 19: 1223-1230
- Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions.J Clin Invest. 2004; 114: 659-668
- Amelioration of diabetic nephropathy in SPARC-null mice.J Am Soc Nephrol. 2003; 14: 968-980
- Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development.J Lipid Res. 2008; 49: 521-530
- Platelet derived growth factor and transforming growth factor-beta1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells.Arterioscler Thromb. 1993; 13: 1026-1036
- SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance.J Clin Invest. 2007; 118: 364-375
- Mouse models of diabetic nephropathy.J Am Soc Nephrol. 2009; 20: 2503-2512
- Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.J Am Soc Nephrol. 2007; 18: 539-550
- Decorin deficiency enhances progressive nephropathy in diabetic mice.Am J Pathol. 2007; 171: 1441-1450
- Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy.Kidney Int. 1994; 46: 430-442
- Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse.Am J Physiol. 1994; 267 (F1094-F1001)
- Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.Proc Natl Acad Sci U S A. 1993; 90: 1814-1818
- Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs.Arterioscler Thromb Vasc Biol. 2002; 22: 55-60
- Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice.Kidney Int. 2004; 66: 1393-1402
- Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.Arch Intern Med. 1998; 158: 998-1004
- Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency.Nephrol Dial Transplant. 1997; 12: 1908-1915
- Renal injury in lipoprotein E-deficient mice.Lab Invest. 2002; 82: 999-1006
- Mouse models of hyperlipidemia and atherosclerosis.Front Biosci. 2001; 6: D515-D525
- Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.Diabetes. 1996; 45: 522-530
- Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.Proc Natl Acad Sci U S A. 2000; 97: 8015-8020
- Transforming growth factor-beta regulates production of proteoglycans by mesangial cells.Kidney Int. 1990; 37: 689-695
- Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice.J Am Soc Nephrol. 1999; 10: 271-280
- Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein Kinase signaling downstream of Smad signaling.J Biol Chem. 2003; 278: 11041-11049
- Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes.J Investig Med. 2007; 55: 18-25
- Elevated levels of beta defensin-1 mRNA in diabetic kidneys of GK rats.Biochem Biophys Res Commun. 2003; 310: 513-521
- Primary human glomerular endothelial cells produce proteoglycans, and puromycin affects their posttranslational modification.Am J Physiol Renal Physiol. 2005; 288: F748-F756
- Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome.Am J Physiol Renal Physiol. 2006; 291: F722-F730
- Biglycan, a nitric oxide-regulated gene, affects adhesion, growth, and survival of mesangial cells.J Biol Chem. 2003; 278: 26227-26237
- Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.Nature. 1992; 360: 361-364
- Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors.J Biol Chem. 2009; 284: 24035-24048
- Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury.Am J Pathol. 2004; 165: 383-396
- Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.Biochem J. 1994; 302: 527-534
- Negative regulation of transforming growth factor-beta by the proteoglycan decorin.Nature. 1990; 346: 281-284
- Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis.Exp Mol Pathol. 2005; 78: 17-24
- Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung.Am J Physiol Lung Cell Mol Physiol. 2001; 280: L1327-L1334
- Increased decorin mRNA in diabetic mouse kidney and in mesangial and tubular cells cultured in high glucose.Am J Physiol. 1998; 275: F827-F832
- Impact of genetic background on nephropathy in diabetic mice.Am J Physiol Renal Physiol. 2006; 290: F214-F222
- Characterization of susceptibility of inbred mouse strains to diabetic nephropathy.Diabetes. 2005; 54: 2628-2637
- Can murine diabetic nephropathy be separated from superimposed acute renal failure?.Kidney Int. 2005; 68: 391-398
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med. 1998; 339: 1349-1357
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002; 360: 7-22
- Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).JAMA. 2002; 288: 2998-3007
- Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.N Engl J Med. 2009; 360: 1395-1407
Supported in part by grants from the Department of Veterans Affairs ( BX000622 to L.R.T.), the American Diabetes Association and the Order of the Amaranth (L.R.T.), the National Institutes of Health ( RR020171 to L.R.T.), and Deutsche Forschungsgemeinschaft ( SFB 815 , project A5 to L.S.).
User LicenseElsevier user license |
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy